## Fen Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/30766/publications.pdf

Version: 2024-02-01

128 papers

1,442 citations

448610 19 h-index 35 g-index

134 all docs

134 docs citations

134 times ranked

1867 citing authors

#	Article	IF	CITATIONS
1	Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation. Transplant Infectious Disease, 2022, 24, .	0.7	2
2	Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. Journal of Hematology and Oncology, 2022, 15, 22.	6.9	24
3	A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer, 2022, , .	2.0	5
4	Comparable meibomian gland changes in patients with and without ocular graft-versus-host disease after hematopoietic stem cell transplantation. Ocular Surface, 2022, 25, 1-7.	2.2	4
5	Metagenomic Profiling of the Ocular Surface Microbiome in Patients After Allogeneic Hematopoietic Stem Cell Transplantation. American Journal of Ophthalmology, 2022, 242, 144-155.	1.7	7
6	A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. Leukemia, 2021, 35, 2054-2063.	3.3	15
7	Wnt/ $\hat{l}^2$ -catenin signaling mediates the abnormal osteogenic and adipogenic capabilities of bone marrow mesenchymal stem cells from chronic graft-versus-host disease patients. Cell Death and Disease, 2021, 12, 308.	2.7	4
8	Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia. Frontiers in Oncology, 2021, 11, 554503.	1.3	8
9	Metagenomic next-generation sequencing for identifying pathogens in central nervous system complications after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 1978-1983.	1.3	14
10	Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with <scp>MDSâ€EB</scp> â€I or <scp>MDSâ€EB</scp> â€2. International Journal of Cancer, 2021, 149, 1109-1120.	2.3	6
11	Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia. Cancer Letters, 2021, 510, 59-66.	3.2	2
12	Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. JAMA Network Open, 2021, 4, e2115991.	2.8	12
13	Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A singleâ€center retrospective study. Cancer Medicine, 2021, 10, 8497-8506.	1.3	8
14	Herpesvirus Infections of Intestinal Tract in the Patients with Intestinal Graft-Versus-Host Diseases: Laboratory Diagnosis Based on DNA Detection By Real-Time Quantitative PCR in Feces Samples. Blood, 2021, 138, 1793-1793.	0.6	0
15	Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Acute and Chronic Steroid-Refractory Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4884-4884.	0.6	1
16	The Impact of CD19 Expression Combined with Measurable Residual Disease on Post-Remission Treatment and Outcome in Adult t(8;21) Acute Myeloid Leukemia. Blood, 2021, 138, 4445-4445.	0.6	0
17	Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Phâ^' high-risk B-cell acute lymphoblastic leukemia. Chinese Medical Journal, 2021, Publish Ahead of Print, .	0.9	4
18	IKZF1deletions Coupled with CD20 Expression Represents a Novel High-Risk Subtype in Adult B-Cell Progenitor Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4474-4474.	0.6	0

#	Article	IF	CITATIONS
19	Mesenchymal Stromal Cells Plus Anti-CD25 Antibody and Calcineurin Inhibitors for Steroid-Resistant Acute Graft-Versus-Host Disease: A Multicenter, Randomized, Phase 3 Trial. Blood, 2021, 138, 260-260.	0.6	O
20	Retrospective Analysis of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4877-4877.	0.6	2
21	Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes. Blood Cancer Journal, 2021, 11, 195.	2.8	8
22	Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia, 2020, 34, 1433-1443.	3.3	73
23	Ponatinib therapy in recurrent Philadelphia chromosomeâ€positive central nervous system leukemia with T315I mutation after Alloâ€HSCT. International Journal of Cancer, 2020, 147, 1071-1077.	2.3	10
24	Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A singleâ€center retrospective study. Cancer Medicine, 2020, 9, 6244-6255.	1.3	9
25	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncology, The, 2020, 21, 1201-1212.	5.1	209
26	Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vsHost Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 1505.	2.2	5
27	Graft-vs-Host Disease–Induced Hyperthyroidism in a Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. Transplantation Proceedings, 2020, 52, 2854-2857.	0.3	2
28	Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. Journal of Hematology and Oncology, 2020, 13, 18.	6.9	36
29	Cidofovir, a Choice for Salvage Treatment of CMV Infection in the Patients with Haploidentical Hematopoitic Stem Cell Transplantation. Blood, 2020, 136, 40-41.	0.6	1
30	Prophylactic Donor Lymphocyte Infusion Based on Two Different Time for Preventing Relapse in Advanced Acute Leukemia Undergoing Allo-HSCT: Comparison of Two Independent Prospective Cohorts. Blood, 2020, 136, 7-8.	0.6	0
31	DAC-Based Conditioning Regimen Versus Standard Conditioning Regimen for Myelodysplastic Syndrome. Blood, 2020, 136, 31-32.	0.6	0
32	Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 26-27.	0.6	4
33	Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC Medicine, 2019, 17, 156.	2.3	55
34	Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1944-1955.	2.0	38
35	Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience. Cancer Medicine, 2019, 8, 6549-6558.	1.3	9
36	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Journal of Hematology and Oncology, 2019, 12, 88.	6.9	76

#	Article	IF	CITATIONS
37	Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1674-1681.	2.0	24
38	Expansion of circulating extrafollicular helper T-like cells in patients with chronic graft-versus-host disease. Journal of Autoimmunity, 2019, 100, 95-104.	3.0	7
39	Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study. Infection, 2019, 47, 275-284.	2.3	9
40	The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study. EBioMedicine, 2019, 49, 213-222.	2.7	19
41	Efficacy of Mesenchymal Stem Cells in Bronchiolitis Obliterans Syndrome after Allogeneic HSCT: A Multicenter Prospective Cohort Study. Blood, 2019, 134, 871-871.	0.6	1
42	The Efficacy and Safety of Cidofovir in Salvage Therapy for CMV Infection in the Patients with Haploid Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 5659-5659.	0.6	0
43	Cytomegalovirus Infection in Bone Marrow-Derived Mesenchymal Stem Cells: Implications for Functions and Exploration of Relevant Mechanisms. Blood, 2019, 134, 5005-5005.	0.6	0
44	Preemptive Therapy Based on the Load and Time of EBV-Emia for Preventing EBV Related PTLD after Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study. Blood, 2019, 134, 5693-5693.	0.6	0
45	Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study. Blood, 2019, 134, 3303-3303.	0.6	0
46	A retrospective comparison of EscherichiaÃ-¿½coli and polyethylene glycol‑conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncology Letters, 2018, 15, 75-82.	0.8	10
47	Effect of sorafenib on the outcomes of patients with FLT3â€ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Cancer, 2018, 124, 1954-1963.	2.0	51
48	Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients. Frontiers in Immunology, 2018, 9, 669.	2.2	57
49	Regulatory γδT cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation. Journal of Translational Medicine, 2018, 16, 144.	1.8	21
50	Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT. Blood, 2018, 132, 2129-2129.	0.6	1
51	Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5736-5736.	0.6	1
52	Efficacy and Safety of Ruxolitinib in Treatment of Steroid Refractory/Refractory Acute Graft-Versus-Host Disease: A Prospective Multicenter Research. Blood, 2018, 132, 5724-5724.	0.6	0
53	Intestinal Microbiota at Neutrophil Engraftment Can Predict Acute Graft-Versus-Host Disease in the Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 2122-2122.	0.6	1
54	Expansion of Peripheral Extra-Follicular Helper T Cells in Patients with Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 4583-4583.	0.6	0

#	Article	IF	CITATIONS
55	The Outcomes of Epstein-Barr Virus Specific T Cells from Different Sources for EBV Infections in Recipients of Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 3330-3330.	0.6	O
56	Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1311-1319.	2.0	66
57	Haploidentical transplantation compared with matched siblingÂand unrelated donor transplantation for adults with standardâ€risk acute lymphoblastic leukaemia in first complete remission. British Journal of Haematology, 2017, 179, 120-130.	1.2	70
58	Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia. Journal of Hematology and Oncology, 2017, 10, 135.	6.9	39
59	Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell transplant compared with matched sibling and unrelated donor. Oncotarget, 2017, 8, 26505-26514.	0.8	14
60	Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. International Journal of Hematology, 2016, 104, 485-490.	0.7	30
61	Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2016, 9, 40.	6.9	17
62	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncolmmunology, 2016, 5, e1139274.	2.1	24
63	Increase of Regulatory Î <sup>3</sup> δT Cells Reduces the Incidence of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2230-2230.	0.6	2
64	Haploidentical Hematopoietic Stem Cell Transplant Compared with Matched Sibling and Unrelated Transplants in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia in First Complete Remission. Blood, 2016, 128, 2299-2299.	0.6	2
65	Influence of Lower Dose Antithymocyteglobulin As Conditioning Regimen on Viral Infection after Haploidentical Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 825-825.	0.6	2
66	Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. Oncotarget, 2016, 7, 32579-32591.	0.8	31
67	Bone Marrow Derived Mesenchymal Stromal Cells Reduce the Incidence of Chronic Graft-Versus-Host Disease after Allogenetic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 4578-4578.	0.6	1
68	Two Doses of Antithymocyteglobulin As Graft-Versus-Host Disease Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation: A Multicenter Prospective Study. Blood, 2016, 128, 4603-4603.	0.6	1
69	Expression of Regulatory γδT Cells in Patients with Acute Graft-Versus-Host Disease. Blood, 2016, 128, 5784-5784.	0.6	0
70	Autoimmune Hematological Diseases Following Haploidentical Donor Hematopoietic Stem Cell Transplant Compared with Matched Sibling and Unrelated Donor. Blood, 2016, 128, 5861-5861.	0.6	0
71	The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma. PLoS ONE, 2015, 10, e0126615.	1.1	22
72	Immunomodulation Effects of Mesenchymal Stromal Cells on Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 97-104.	2.0	145

#	Article	IF	CITATIONS
73	Mesenchymal Stem Cell As a Salvage Treatment for Patients with Refractory Bronchiolitis Obliterans Syndrome after Allogenetic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 855-855.	0.6	1
74	Coagulation Disorder after Treatment of Pegaspargase and L-Asparaginase. Blood, 2015, 126, 4876-4876.	0.6	0
75	Intrathecal Rituximab for EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement Unresponsive to Intravenous Rituximab-Based Treatments: A Prospective Study. Blood, 2015, 126, 4352-4352.	0.6	0
76	Glasgow Prognostic Score Is Superior to Other Inflammation-Based Scores in Predicting Survival of Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 1454-1454.	0.6	0
77	CD163+ Tumor Associated Macrophages Predict Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 5023-5023.	0.6	1
78	A Comparison of Lamivudine and Entecavir for the Prophylaxis of Hepatitis B Virus Reactivation in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institutional Experience. Blood, 2015, 126, 2026-2026.	0.6	0
79	Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leukemia Research, 2014, 38, 694-698.	0.4	39
80	Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial. Biology of Blood and Marrow Transplantation, 2014, 20, 236-242.	2.0	26
81	Antifungal Agents for Secondary Prophylaxis Based on Response to Initial Antifungal Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Prior Pulmonary Aspergillosis. Biology of Blood and Marrow Transplantation, 2014, 20, 1198-1203.	2.0	21
82	Continuous intravenous injection of Mesna can effectively prevent Hemorrhagic cystitis in hematopoietic stem cell transplantation and retain the Mesna's concentration in urine: 394 cases reported within 11 years. Blood, 2014, 124, 2483-2483.	0.6	1
83	Autologous HSCT Followed By Immunotherapy and Maintenance Chemotherapy Compared with Allogeneic HSCT for Intermediate-Risk Molecules/Cytogenetics Acute Myeloblastic Leukemia in First Complete Remission. Blood, 2014, 124, 3949-3949.	0.6	2
84	The Prevalent, Features and Prognostic Impact of Deletion p16 in Patients with Adult Acute Lymphoblastic Leukemia. Blood, 2014, 124, 5351-5351.	0.6	0
85	Utility of F-18 FDG PET/CT for the Diagnosis and Therapeutic Management of Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type. Blood, 2014, 124, 1704-1704.	0.6	0
86	The Prognostic Significance of Tumor-Associated Macrophages and NK Cells in Patients with Diffuse Large B-Cell Lymphoma Treated with RCHOP. Blood, 2014, 124, 5390-5390.	0.6	0
87	Inhibition of Siah2 Ubiquitin Ligase By Vitamin K3 Attenuates Hypoxia and Blocks K562-R Cells Resistance. Blood, 2014, 124, 5214-5214.	0.6	0
88	Role of Allogeneic Hematopoietic Stem Cell Transplantation for None Remission / Advanced Acute Myeloid Leukemia with Flt3-ltd Mutations: Outcomes of 15 Newly Diagnosed Patients from a Single Institution. Blood, 2014, 124, 5936-5936.	0.6	0
89	New Insight into Epstein-Barr Virus-Associated Biological Behavior of Aggressive Natural Killer Cell Leukemia. Blood, 2014, 124, 3002-3002.	0.6	0
90	Role of Surgical Resection in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Prior Pulmonary Aspergillosis. Blood, 2014, 124, 5846-5846.	0.6	0

#	Article	IF	Citations
91	Established Standards of Minimal Residual Disease Detected By Multiparametric Flow Cytometry in Acute Leukemia. Blood, 2014, 124, 5262-5262.	0.6	O
92	The Clinical Significance of Minimal Residual Disease Detected By Multiparametric Flow Cytometry in Acute Leukemia. Blood, 2014, 124, 5261-5261.	0.6	0
93	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia: Comparison of Outcomes Among HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors and HLA-Mismatched Family Donors. Blood, 2014, 124, 5917-5917.	0.6	0
94	The Expression of CD44v6 Predicts Poor Outcome in Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP. Blood, 2014, 124, 5386-5386.	0.6	0
95	The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology, 2013, 18, 151-157.	0.7	17
96	Mesenchymal Stem Cells Vs. Mesenchymal Stem Cells Combined With Cord Blood For Treating Engraftment Failure Following Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective Study. Blood, 2013, 122, 3693-3693.	0.6	1
97	Epstein-Barr Virus Infection In Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation: The Role Of Cytomegalovirus. Blood, 2013, 122, 4555-4555.	0.6	0
98	Immunologic Effects Of Mesenchymal Stem Cells In The Treatment Of Refractory Acute Graft-Versus-Host Disease. Blood, 2013, 122, 2056-2056.	0.6	0
99	Fungus Bloodstream Infection In Patients With Haematological Malignanciest. Blood, 2013, 122, 4734-4734.	0.6	0
100	Mesenchymal Stem Cell As a Salvage Treatment For Refractory Acute Graft-Versus-Host Disease: a Matched Pair Analysis. Blood, 2013, 122, 3294-3294.	0.6	0
101	ANKL Is Strongly EBV-Related, Frequent In Chromosome Aberrations and Gene Mutations, LMP2A/LMP1-CDK6-MDM2-CD44-Positive and Might Be Sensitive To L-Asparaginase-Containing Regimen. Blood, 2013, 122, 3012-3012.	0.6	1
102	Continuous Intravenous Injection Of Mesna Can Reduce Acute Hemorrhagic Cystitis Occurrence Rate In Hematopoietic Stem Cell Transplantation: 359 Allo-HSCT Cases Report. Blood, 2013, 122, 4556-4556.	0.6	0
103	Sequential Intensified Conditioning Followed By Early Tapering Immunosuppressants and DLI In Allogeneic Hematopoietic Stem Cell Transplantation For Refractory/Recurrent T Lymphoblastic Lymphoma. Blood, 2013, 122, 2122-2122.	0.6	0
104	The Effect Of Prior Chemotherapy Courses With MD-AraC On The Hematopoietic Stem Cell Mobilization. Blood, 2013, 122, 5446-5446.	0.6	0
105	Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies. Blood, 2013, 122, 5509-5509.	0.6	0
106	Sequential Intensiï¬ed Conditioning Followed By Tapering Of Prophylactic Immunosupressants and Donor Lymphocyte Infusions In Allogeneic Hematopoietic Stem Cell Transplantation For Refractory Leukemia. Blood, 2013, 122, 702-702.	0.6	0
107	Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission. Blood, 2013, 122, 3290-3290.	0.6	0
108	Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4637-4637.	0.6	0

#	Article	IF	CITATIONS
109	HLA Polymorphisms and Epstein-Barr Virus Infection In The Recipient Of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3291-3291.	0.6	O
110	STAT3 Predicts Poor Outcome In Patients With Advanced Diffuse Large B Cell Lymphoma. Blood, 2013, 122, 5069-5069.	0.6	0
111	A Two-Year Follow-Up Of a Prospective Study Of Intensified Conditioning Regimen With High-Dose-Etoposide Allogeneic Hematopoietic Stem Cell Transplantation For Adult Acute Lymphoblastic Leukemia In China. Blood, 2013, 122, 4570-4570.	0.6	0
112	The E3 Ubiquitin Ligases Siah2 Contributes To Imatinib Resistance In Chronic Myeloid Leukemia In Hypoxia Condition. Blood, 2013, 122, 2530-2530.	0.6	0
113	Antithymocyte Globulin (ATG) Plus Cyclosporine (CsA) and Combined with Cord Blood Infusion Is Superior to ATG Plus Csa for the Treatment of Severe Aplastic Anemia. Blood, 2012, 120, 4397-4397.	0.6	0
114	Effect of Knockdown of CD44 Expression by shRNA On Biologicalfeatures of Activated B-Cell-Like Diffuse Large B Cell Lymphoma Cell Line. Blood, 2012, 120, 5080-5080.	0.6	0
115	Effect of Antithymocyte Globulin Dosage for Prophylactic Gvhd On Epstein-Barr Virus Reactivation and Diseases in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4486-4486.	0.6	0
116	The Significance of CD44ICD in Difuse Large B- Cell Lymphoma Cell Line SUDHL2 and the Preliminary Study On the Mechanism. Blood, 2012, 120, 5087-5087.	0.6	0
117	Comparative Efficacy of Homoharringtonine Plus Cytarabine and Decitabine in Patients with MDS/AML. Blood, 2012, 120, 4340-4340.	0.6	0
118	Molecular Monitoring and Stepwise Preemptive Therapy to Prevent Epstein-Barr Virus-Associated Diseases After Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2012, 120, 3067-3067.	0.6	0
119	Secondary Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients. Blood, 2012, 120, 4140-4140.	0.6	0
120	Analysis of Infection-Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Refractory/Relapse Acute Leukemia. Blood, 2012, 120, 4513-4513.	0.6	4
121	The Comparison Between Long-Term and Short-Term Administration of Itraconazole for Primary Antifungal Prophylaxis in Recipients of Allogeneic Hematopoietic Stem Cell: A Multicenter, Randomized, Open-Label Trial (NCT01160952). Blood, 2012, 120, 1930-1930.	0.6	0
122	Improvement in Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation Upon Administration of Mesenchymal Stem Cells From Third-Party Donors: A Pilot Prospective Study. Blood, 2012, 120, 1904-1904.	0.6	0
123	The Management of EBV-Associated Post-Transplant Lymphoproliferative Disorder with Central Nervous System Involvement After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 1959-1959.	0.6	1
124	Granulocyte Colony-Stimulating Factor-Mediated Immunoregulation Via Inducing Blood Cells Expressing Human Leucocyte Antigen-G Blood, 2012, 120, 3051-3051.	0.6	0
125	Herpesvirus-Associated Central Nervous System Diseases After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 4139-4139.	0.6	0
126	The Initial Research on Relationship of Transcription Factor C/EBPÎ $\pm$ and Raji Cell Line. Blood, 2011, 118, 4650-4650.	0.6	0

## Fen Huang

#	Article	IF	CITATIONS
127	Association Between MDSCs and Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation,. Blood, 2011, 118, 4069-4069.	0.6	O
128	Prognostic Factors in Diffuse Large B Cell Lymphoma, A Preliminary Study Blood, 2009, 114, 5006-5006.	0.6	0